Analysing Outcomes in MCL

An analysis of outcomes in patients with mantle cell lymphoma (MCL) following failure of first-line treatment was undertaken.

The study also evaluated the prognostic role of Secondary Mantle Cell Lymphoma Prognostic Index (sec MIPI). Findings were presented at the 2014 American Society of Hematology annual meeting. The analysis was undertaken in 388 patients with most having advanced disease. Following first-line treatment, there were 179 relapses or progressions and 70 deaths.

At the time of first relapse, the sec MIPI was low in 12.7% of patients; intermediate in 32.1% of patients and high in 59.8% of patients. Median progression-free survival (PFS) following initial diagnosis was 2.9 years but each subsequent relapse resulted in significantly shorter PFS.

Read more here.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Are you aware cancer patients can experience chemo brain without ever receiving chemotherapy?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.